630-0012 Pulmonx LIBERATE Study
Research type
Research Study
Full title
Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment of Emphysema
IRAS ID
167412
Contact name
Bridget Hurley
Contact email
Sponsor organisation
Pulmonx Corporation
Clinicaltrials.gov Identifier
Duration of Study in the UK
7 years, 7 months, 31 days
Research summary
Emphysema is a serious disease afflicting more than four million people worldwide. It is one form of Chronic Obstructive Pulmonary Disease, or COPD. Emphysema causes the lungs to lose the ability to move air in and out normally and to efficiently absorb oxygen. Eventually, breathing becomes more difficult as damaged parts of the lungs trap air. As the disease advances, the damaged, inelastic areas of the lung progressively expand within the chest cavity, leaving one constantly feeling out of breath.
The purpose of this research is to study a medical device that is designed to reduce the volume of the lung. This device is called the Pulmonx Endobronchial Valve (EBV). The EBV is a one-way valve that blocks off the diseased lung section to inhaled air but lets the trapped air already inside the area escape. With placement of the EBV, the diseased part of the lung collapses; this allows the healthier parts of the lung to expand.
The EBV can be placed by a doctor in a diseased section of the lungs using bronchoscopy. Bronchoscopy is a way to access the lungs using a small tube with a camera on the end. With bronchoscopy, a physician can reach the airways in the lung by passing the tube through either the mouth or nose. Use of bronchoscopy for performing lung volume reduction may have fewer risks than surgery and have reduced recovery time.
This study is designed to investigate the safety and effectiveness of the Pulmonx EBV for treating emphysema symptoms as compared to a standard medical therapy program alone.The purpose of this research is to study a medical device that is designed to reduce the volume of the lung. This device is called the Pulmonx Endobronchial Valve (EBV). The EBV is a one-way valve that blocks off the diseased lung section to inhaled air but lets the trapped air already inside the area escape. With placement of the EBV, the diseased part of the lung collapses; this allows the healthier parts of the lung to expand.
The EBV can be placed by a doctor in a diseased section of the lungs using bronchoscopy. Bronchoscopy is a way to access the lungs using a small tube with a camera on the end. With bronchoscopy, a physician can reach the airways in the lung by passing the tube through either the mouth or nose. Use of bronchoscopy for performing lung volume reduction may have fewer risks than surgery and have reduced recovery time.
This study is designed to investigate the safety and effectiveness of the Pulmonx EBV for treating emphysema symptoms as compared to a standard medical therapy program alone.REC name
London - Stanmore Research Ethics Committee
REC reference
15/LO/0900
Date of REC Opinion
10 Jul 2015
REC opinion
Favourable Opinion